News

Welcome Biogen to AmCham!

Dec 09, 2020
Biogen Latvia, a US-based company and one of the world's largest biotechnology companies for the development and commercialization of therapies specializing in neurological disease research, has joined the Chamber as a Corporate Contributing member. We warmly welcome them to AmCham!

Biogen was founded in 1978 and is one of the largest biotech companies, employing more than 7400 employees worldwide. The company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. Biogen's turnover in 2019 was 14.4 billion US dollars.

In the Chamber it will be represented by Mikko Fernström, General Manager of Biogen Latvia.

Mikko Fernström, General Manager of Biogen Latvia about joining the Chamber: "We are very pleased to be part of AmCham Latvia community and are looking forward to drive innovation forward in Latvia". 

< Back to News

Categories

Kyndryl Latvia

Feedback

Membership is an attestation that we belong to the modern Latvian business community.

Dace Silava-Tomsone, Managing Partner, COBALT

AmCham is an invaluable resource that keeps us up to date with business issues and opportunities.

Mantautas Paskevicius, Country Manager of Strategic Staffing Solutions International